Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @AchillionPharma
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @AchillionPharma
-
Prikvačeni tweet
Pleased to share that Achillion has been acquired by
@AlexionPharma. As part of Alexion, we remain driven to transform the lives of people and families affected by diseases of the complement system. http://bit.ly/36z2Y51Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Today,
#ACHN announced positive top-line results for danicopan (ACH-4471) from the Phase 2#PNH combination therapy trial with eculizumab at#ASH2019. Be sure to check out the details here: http://bit.ly/2RxPIth pic.twitter.com/T6YDqJOOrj
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ACHN is pleased to announce today that the EMA grants PRIME (Priority Medicines) designation to danicopan (ACH-4471) for treatment of#PNH patients who are not adequately responding to a C5 inhibitor.http://bit.ly/2O3mdNXHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today and every day, we honor those who bravely served our country.
#VeteransDay#ACHNpic.twitter.com/ZeW585aBNv
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today,
#ACHN announced that the US FDA has accepted the Investigational New Drug Application (IND) for ACH-5228, our second-generation oral factor D inhibitor. See the press release for more detail:http://bit.ly/34R77kkHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today,
#ACHN reported third quarter 2019 financial results and provided a corporate update. See the press release for more detail:http://bit.ly/2NMENZiHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
We are pleased to announce today the acceptance of two abstracts for poster presentation at
#ASH19 of P2 clinical data for our lead investigational oral factor D inhibitor, danicopan (ACH-4471). Check out the press release for more details:http://bit.ly/2NJuJ3nHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
@AchillionPharma to be acquired by@AlexionPharma, accelerating our objective of bringing novel therapies to market faster to improve lives of patients. For important information read here:http://bit.ly/2qk23pAHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mark your calendars!
#ACHN’s CEO, Joseph Truitt, will be presenting at the 2019 Cantor Fitzgerald Global Healthcare Conference on October 3rd at 8:55 a.m. ET http://bit.ly/2ntygsZ pic.twitter.com/ubjFchRYlK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ACHN is pleased to announce that the FDA has granted Breakthrough Therapy Designation for danicopan (ACH-4471) in combination with a C5 monoclonal antibody for the treatment of patients with#PNH who are sub-optimal responders to a C5 inhibitor alone.http://bit.ly/2mBAIgDHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ACHN’s CEO, Joseph Truitt, will be presenting at the Baird 2019 Global Healthcare Conference on September 5th! http://bit.ly/2ZCCxHW#BairdHCCpic.twitter.com/QYg7wulC3o
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today,
#ACHN reported second quarter 2019 financial results and provided a corporate update. See the PR for more detail:http://bit.ly/2Kzxy5lHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Be sure to check out
#ACHN’s July corporate presentation including new topline Ph1 multiple ascending dose study data for ACH-5228 in healthy volunteers, our investigational next-gen oral factor D inhibitor http://bit.ly/2LzwPULHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Today we announced positive results for ACH-5228, our investigational next-gen oral factor D inhibitor, from the Ph1 multiple ascending dose study in healthy volunteers. Check out the official PR for more detail: http://bit.ly/2y2qiZT
#RareDisease#ACHNHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Wishing you all a safe and happy
#independenceday from the#ACHN team!pic.twitter.com/CXmwRFXhdI
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Don’t forget to check out
#ACHN’s presentation at the 2019 JMP Securities Life Sciences Conference. Watch the live webcast:http://bit.ly/2WSsywKHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
It was great connecting with the
#PNH community at#EHA2019. In case you missed the oral presentation on our investigational treatment danicopan (formerly ACH-4471) in untreated#PNH patients, you can find it here: http://bit.ly/2XiBxvyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you’re in attendance, don’t forget to check out the oral presentation tomorrow from
#ACHN’s Phase 2 data in untreated#PNH patients at#EHA2019.pic.twitter.com/7bdsMj7aBo
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#ACHN’s CFO and CMO will be presenting at the 2019 JMP Securities Life Sciences Conference on June 20th. http://bit.ly/2MI8E7U pic.twitter.com/aU36YTqtmp
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.